Ezra Cohen to Risk Factors
This is a "connection" page, showing publications Ezra Cohen has written about Risk Factors.
Connection Strength
0.245
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials. 2014 Nov 29; 15:469.
Score: 0.059
-
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. J Geriatr Oncol. 2013 Oct; 4(4):327-33.
Score: 0.053
-
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 12 26; 17(1):429.
Score: 0.021
-
Selection of Head and Neck Cancer Patients for Intensive Therapy. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):157-166.
Score: 0.021
-
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
Score: 0.016
-
Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer. Cancer. 2015 Apr 15; 121(8):1303-11.
Score: 0.015
-
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
Score: 0.014
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
Score: 0.012
-
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. Tex Dent J. 2012 May; 129(5):491-507.
Score: 0.012
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.012
-
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010 May; 141(5):509-20.
Score: 0.011